Business Wire

Experience the Future of Smarter AI for All at Lenovo’s Tenth Annual Global Tech World Event

3.10.2024 16:40:00 EEST | Business Wire | Press release

Share

On October 15, 2024, Lenovo will host its annual global innovation event, Tech World, in Bellevue, Washington. This marks the 10th consecutive year of the event and reflects a decade of innovation and transformation from the company. This year’s event will explore how Lenovo is delivering on the promise of artificial intelligence (AI) with end-to-end solutions fueling its mission of Smarter AI for All. Technology featured will include ground-breaking AI for Good projects, hybrid AI to empower both individuals and enterprises, and proven ways to fast-track and deploy generative AI.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003339216/en/

What's next for AI? Join us October 15, 2024 at #LenovoTechWorld to hear top industry leaders discuss the future of AI innovation for all. Learn more: https://lnv.gy/3ZxcPr5 (Graphic: Business Wire)

The company will also discuss its ongoing investment and collaboration with partners to deliver the most advanced and comprehensive AI-ready, AI-enabled, and AI-optimized AI devices, infrastructure, solutions, and services for customers. The industry’s top partners will all join Lenovo on stage to discuss what’s next and build on the key product launches and new services announced earlier this year, including:

  • With Intel, Lenovo was among the first to launch AI-enabled PCs with Intel Core Ultra processors in the beginning of this year.
  • With AMD, Lenovo brought AI laptops with 3rd Gen Ryzen AI processors to market across consumers, commercial, and SMB users.
  • With Qualcomm and Microsoft, Lenovo announced the first Copilot+ PCs powered by Snapdragon X Elite: the Lenovo Yoga Slim 7x and ThinkPad T14s Gen 6.
  • With NVIDIA, Lenovo launched new Hybrid AI solutions that deliver the powerful generative AI applications to every enterprise and cloud to bring transformation capabilities to every industry through new AI professional services and Lenovo’s Spatial Computing Appliance of digital twin technology.

Tech World will feature a keynote session by Lenovo Chairman and CEO Yuanqing Yang, who will discuss Lenovo’s latest innovations and strategies in pursuit of “Smarter AI for All.” He will showcase the technologies making hybrid AI a reality for everyone, everywhere—at home, at work, and on the move.

Attendees can tune in in-person and virtually to experience how Lenovo uses hybrid AI to support large and small organizations. The latest technologies accelerate AI outcomes, scale and evolve private AI, and gain affordable and scalable access to metered GPU resources.

Additional Speakers include Lenovo’s newly appointed Chief Technology Officer, Dr. Tolga Kurtoglu, Lenovo’s President of the Emerging Technology Group, Dr. Yong Rui, alongside partner speakers like Lisa Su, Chair and CEO, AMD; Pat Gelsinger, CEO, Intel; Satya Nadella, Chairman and CEO, Microsoft; Mark Zuckerberg, Founder and CEO, Meta; and Jensen Huang, Founder and CEO, NVIDIA .

Through virtual content that can be explored anytime, Tech World ‘24 will be live-streamed across multiple time zones and hosted on-demand following the main broadcast. To register and see a full agenda of speakers, please visit Lenovo Tech World ’24.

Watch a decade of highlights from previous Tech World events:

About Lenovo

Lenovo is a US$57 billion revenue global technology powerhouse, ranked #248 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a pocket-to cloud portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241003339216/en/

Contacts

Stuart Gill
Director of Global Media Relations
sgill@lenovo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release

NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release

Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release

IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye